Study of Bulevirtide in Participants With Chronic Hepatitis D Infection
← catalyst calendarNCT05718700 · readout ≤ 711 d
Sponsored by Gilead Sciences (industry) · GILD — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
170actual
Sites
53
Countries
Austria, France, Germany +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-02-07 | actual | When the study began enrolling |
| Primary completion | Jul 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jul 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2023-02-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-11-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Chronic Hepatitis D Infection
Intervention
- Drug: Bulevirtide — also filed as Hepcludex®
Primary outcome
what the primary-completion date above is the date OFExposure-adjusted Incidence of Participants With Liver-related Event: Hepatic Decompensation, Hepatocellular Carcinoma (HCC), Liver Transplantation, and Liver-related Death
measured Up to 144 weeks
Permalink · GILD's whole pipeline · Catalyst calendar · Every registered study · What changed